Lite Strategy, Inc.
LITS - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$34.06M
Close$
$0.17
85.3% downside
Current Fair Value
85.3% downsideOvervalued by 85.3% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $34.06 Million |
|---|---|
| Enterprise Value | $28.35 Million |
| Earnings per Share | $-2.06 |
| Beta | 0.04 |
| Outstanding Shares | 34,617,171 |
Return
| Return on Equity | -170.94% |
|---|---|
| Return on Assets | -166.66% |
| Return on Invested Capital | -139.49% |
Valuation & Multiples
| P/E Ratio | -0.12 |
|---|---|
| PEG | -0.03 |
| Price to Sales | - |
| Price to Book Ratio | 1.12 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.49 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Last Earnings Call
Report Date
September 28, 2026
EPS Estimate
$-3.12
Consensus analyst estimateRevenue Estimate
$5.41 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-3.12
Consensus analyst estimateRevenue Estimate
$5.41 M
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.03, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.0333▲ 3.33% |
|---|---|
| Total Calls | 687,200▲ 855.77% |
| Total Puts | 22,900▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 88.34%▼ 0.06% |
|---|---|
| Total Invested | $5.43M▼ 20.55% |
| Investors Holding | 390% |
About MEI Pharma Inc
5 employees
CEO: Daniel Gold
Lite Strategy, Inc. is a pharmaceutical company currently in the clinical development phase, primarily dedicated to creating novel treatments for various forms of cancer. Among its key initiatives, the company is advancing ME-344, an int...